Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oricell Therapeutics has announced the clearance of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for OriCAR-017, a new CAR-T cell therapy targeting GPRC5D, for the treatment of relapsed/refractory multiple myeloma (R/R MM).
The POLARIS study data demonstrated that all 10 patients with R/R MM responded to OriCAR-017 therapy per IMWG criteria. Credit: Louis Reed on Unsplash.
Subscribe to our email newsletter
The approval allows Oricell to commence clinical development of OriCAR-017 in the US, with immediate effect.
Utilising Oricell’s platforms, including OriAb antibodies, OriCAR construct, and unique CMC know-how, OriCAR-017 is designed to achieve optimal binding, persistence, and anti-tumour efficacy from rejuvenated CAR-T cells.
The FDA’s clearance follows the therapy’s IND approval by the NMPA in 2023.
In the POLARIS study, it was observed that all 10 patients with R/R MM responded to OriCAR-017 therapy per IMWG criteria, achieving a 100% overall response rate (ORR) and 80% stringent complete response.
A 100% minimal residual disease (MRD) negative rate was detected at day 28 and further confirmed at month three.
The therapy was found to be well-tolerated, with no reported cases of Immune effector cell-associated neurotoxicity syndrome (ICANS), cerebellar disorder, delayed infections, and only Grade 1/Grade 2 cytokine release syndrome (CRS) that resolved rapidly.
Among the ten R/R MM patients treated, 40% had extramedullary disease (EMD), 50% previously received BCMA CAR-T treatments, 70% had high-risk cytogenetics, and 70% were assessed with an ECOG performance status of two, with 80% at ISS stage II & III.
Oricell co-founder and chief scientific officer Peter He said: “The evidenced superior safety, efficacy and durability profile of OriCAR-017 is truly exciting and will significantly benefit multiple myeloma patients on a global scale.
“Ten years’ R&D cumulates not only OriCAR-017 but also the robust and integrated technology platforms that generate one-of-its-kind CAR-T products for liquid and solid tumours.”
